Fig. 1 · Structure
Documents & Downloads
R1498
Cat. No.
A73301
CAS
303196-31-8
Endogenous Metabolite
R1498 is a multi-target kinase inhibitor primarily affecting Aurora kinases and VEGFR2, associated with tumorigenesis. This compound exhibits notable anti-angiogenic and anti-proliferative properties, demonstrating moderate in vitro growth inhibition across various tumor cell lines with IC50 values in the micromolar range. In vivo studies reveal that R1498 surpasses sorafenib in anti-tumor efficacy within gastric cancer and hepatocellular carcinoma xenograft models, achieving tumor growth inhibition rates exceeding 80% along with substantial tumor shrinkage in select models. Additionally, R1498 effectively inhibits Aurora A activity and reduces tumor vascularization, underscoring its potential as a therapeutic candidate in oncology research.
In Stock
Free Aliquoting for Your Order
Tell us your preferred amount per vial. We’ll confirm the options.
Specifications
| Manufacturer | Adooq Bioscience |
|---|---|
| Actions | Inhibitor |
| CAS Number | 303196-31-8 |
| Applications | Endogenous Metabolite |
| Formula | C18H15ClN4O |
| Molecular Weight | 338.79 |
| SMILES | ClC1=C(C2=NC3=C(C)NN=C3NC4=C2C=C(OC)C=C4)C=CC=C1 |
Storage & Solubility
In Vitro Solubility
Reported Solubility
No reported solubility data are available for this product.
Preparing Stock Solutions
| Concentration | |
|---|---|
Values use four significant digits. Prepare to the final solution volume; this is not the volume of solvent to add.
Stock preparation is unavailable for this product molecular weight.
Calculated stock concentrations do not establish solvent solubility. Refer to the reported solubility data for experimental guidance.
Storage
Store powder at -20°C, keep desiccated.
In powder form, the chemical is stable for 36 months.
In solution, store at -20°C and use within 1 month to prevent loss of potency. Aliquot to avoid multiple freeze/thaw cycles.